SINGAPORE, Oct 20 (The Straits Times/ANN): The National Centre for Infectious Diseases (NCID) has temporarily stopped enrolling Covid-19 patients for a monoclonal antibody trial after the American pharmaceutical company that developed the drug had to halt the trial due to safety concerns last week.
Singapore is only the third country to be involved in the trial after the United States and Denmark, and this is the nation's first Phase 3 monoclonal antibody trial.
Already a subscriber? Log in.
Subscribe to win RM50 Touch 'n Go e-Voucher! More Info
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!